4.4 Review

Controversies and Advances With Testosterone Therapy: A 40-Year Perspective

期刊

UROLOGY
卷 89, 期 -, 页码 27-32

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.urology.2015.11.034

关键词

-

资金

  1. AbbVie
  2. Bayer
  3. Clarus
  4. Endo
  5. Eli Lilly
  6. Pfizer

向作者/读者索取更多资源

Testosterone therapy (TTh) has become highly controversial. There are important health consequences of testosterone deficiency, and meaningful benefits with treatment. There is level 1 evidence that TTh improves sexual function and desire, body composition, and bone density. Concerns regarding cardiovascular risk were based on two deeply flawed retrospective studies and are contradicted by dozens of studies showing cardiovascular benefits of TTh or higher endogenous testosterone, including placebo-controlled studies in men with known heart disease (angina, heart failure). Prostate cancer should no longer be considered a risk of TTh. Testosterone is neither scourge nor panacea-it is just good medicine. (C) 2016 Elsevier Inc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据